Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications

  • Authors:
    • Xingxiang Pu
    • Zhizhong Pan
    • Ying Huang
    • Ying Tian
    • Hongqiang Guo
    • Lin Wu
    • Xuexing He
    • Xinggui Chen
    • Shaodan Zhang
    • Tongyu Lin
  • View Affiliations

  • Published online on: October 10, 2012     https://doi.org/10.3892/ol.2012.963
  • Pages: 249-254
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In colorectal cancer (CRC), KRAS and BRAF mutations in primary tumors are associated with resistance to anti-epidermal growth factor receptor (anti‑EGFR)-based therapies. However, the correlation between KRAS/BRAF mutation in primary tumors and serum has not been well studied. To evaluate the degree of concordance of KRAS/BRAF mutations between the primary tumors and the matched serum samples in CRC, serum and tumor tissues were collected from 115 patients with CRC and KRAS/BRAF mutations were examined by nested polymerase chain reaction (PCR) and direct sequencing. BRAF mutations were present in 3.5% (4/115) of the primary tumor tissue samples and 0.87% (1/115) of the serum samples. In the 4 primary tumors with BRAF mutations, identical mutations were not observed in the corresponding serum samples (κ=-0.016). KRAS mutations were observed in 32.2% (37/115) of the primary tumors and 11.3% (13/115) of the serum samples. Of the 37 tumor cases with KRAS mutations, 9 had identical mutations in the corresponding serum sample, with a concordance rate of 24.3% (9/37). Discordance was observed in 32 (27.8%) patients. The concordance between KRAS mutations in the primary tumors and KRAS mutations in the matched serums was low (κ=0.231). The results of the present study suggest that the possibility of differences in the mutational status of KRAS/BRAF between primary tumors and matched serum samples should be considered when patients are selected for anti-EGFR-based therapies.
View References

Related Articles

Journal Cover

January 2013
Volume 5 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Pu X, Pan Z, Huang Y, Tian Y, Guo H, Wu L, He X, Chen X, Zhang S, Lin T, Lin T, et al: Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications. Oncol Lett 5: 249-254, 2013
APA
Pu, X., Pan, Z., Huang, Y., Tian, Y., Guo, H., Wu, L. ... Lin, T. (2013). Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications. Oncology Letters, 5, 249-254. https://doi.org/10.3892/ol.2012.963
MLA
Pu, X., Pan, Z., Huang, Y., Tian, Y., Guo, H., Wu, L., He, X., Chen, X., Zhang, S., Lin, T."Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications". Oncology Letters 5.1 (2013): 249-254.
Chicago
Pu, X., Pan, Z., Huang, Y., Tian, Y., Guo, H., Wu, L., He, X., Chen, X., Zhang, S., Lin, T."Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications". Oncology Letters 5, no. 1 (2013): 249-254. https://doi.org/10.3892/ol.2012.963